[go: up one dir, main page]

BR0210076A - Preparação de vìrus da influenza inativado, vacina de influenza, métodos para a preparação de um antìgeno de hemaglutinina estável e para a profilaxia da doença ou infecção de influenza em um indivìduo, e, uso de alfa-tocoferol ou de um seu derivado - Google Patents

Preparação de vìrus da influenza inativado, vacina de influenza, métodos para a preparação de um antìgeno de hemaglutinina estável e para a profilaxia da doença ou infecção de influenza em um indivìduo, e, uso de alfa-tocoferol ou de um seu derivado

Info

Publication number
BR0210076A
BR0210076A BR0210076-2A BRPI0210076A BR0210076A BR 0210076 A BR0210076 A BR 0210076A BR PI0210076 A BRPI0210076 A BR PI0210076A BR 0210076 A BR0210076 A BR 0210076A
Authority
BR
Brazil
Prior art keywords
preparation
influenza
individual
tocopherol
infection
Prior art date
Application number
BR0210076-2A
Other languages
English (en)
Inventor
Uwe Eichhorn
Original Assignee
Seachsisches Serumwerk Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113083A external-priority patent/GB0113083D0/en
Priority claimed from GB0204116A external-priority patent/GB0204116D0/en
Application filed by Seachsisches Serumwerk Dresden filed Critical Seachsisches Serumwerk Dresden
Publication of BR0210076A publication Critical patent/BR0210076A/pt
Publication of BRPI0210076A8 publication Critical patent/BRPI0210076A8/pt
Publication of BRPI0210076B1 publication Critical patent/BRPI0210076B1/pt
Publication of BRPI0210076B8 publication Critical patent/BRPI0210076B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PREPARAçãO DE VìRUS DA INFLUENZA INATIVADO, VACINA DE INFLUENZA, MéTODOS PARA A PREPARAçãO DE UM ANTìGENO DE HEMAGLUTININA ESTáVEL E PARA A PROFILAXIA DA DOENçA OU INFECçãO DE INFLUENZA EM UM INDIVìDUO, E, USO DE ALFA-TOCOFEROL OU DE UM SEU DERIVADO". Uma preparação de vírus da influenza inativado é descrita a qual compreende um antígeno de hemaglutinina estabilizado na ausência de tiomersal, ou em níveis baixos de tiomersal, na qual a hemaglutinina é detectável por um ensaio de SRD. A preparação de vírus da influenza pode compreender um excipiente modificador de micela, por exemplo <244>-tocoferol ou um seu derivado em uma quantidade suficiente para estabilizar a hemaglutinina.
BRPI0210076 2001-05-30 2002-05-29 preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato BRPI0210076B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0113083.0 2001-05-30
GB0113083A GB0113083D0 (en) 2001-05-30 2001-05-30 Novel compounds
GB0204116.8 2002-02-21
GB0204116A GB0204116D0 (en) 2002-02-21 2002-02-21 Novel vaccine composition
PCT/EP2002/005883 WO2002097072A2 (en) 2001-05-30 2002-05-29 Influenza vaccine composition

Publications (4)

Publication Number Publication Date
BR0210076A true BR0210076A (pt) 2004-06-22
BRPI0210076A8 BRPI0210076A8 (pt) 2017-05-23
BRPI0210076B1 BRPI0210076B1 (pt) 2020-01-07
BRPI0210076B8 BRPI0210076B8 (pt) 2021-05-25

Family

ID=30445235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210076 BRPI0210076B8 (pt) 2001-05-30 2002-05-29 preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato

Country Status (29)

Country Link
US (2) US7316813B2 (pt)
EP (3) EP2039761A1 (pt)
JP (1) JP4074582B2 (pt)
KR (1) KR100871021B1 (pt)
CN (2) CN1279165C (pt)
AR (1) AR036039A1 (pt)
AT (1) ATE420159T1 (pt)
AU (2) AU2006200742C9 (pt)
BR (1) BRPI0210076B8 (pt)
CA (1) CA2448208C (pt)
CO (1) CO5540349A2 (pt)
CY (1) CY1108930T1 (pt)
CZ (1) CZ298697B6 (pt)
DE (1) DE60230760D1 (pt)
DK (1) DK1407008T3 (pt)
ES (1) ES2318020T3 (pt)
FR (1) FR13C0072I1 (pt)
HU (1) HU229368B1 (pt)
IL (2) IL158931A (pt)
MX (1) MXPA03010944A (pt)
MY (1) MY134424A (pt)
NO (1) NO335212B1 (pt)
NZ (1) NZ529755A (pt)
PL (1) PL206435B1 (pt)
PT (1) PT1407008E (pt)
SI (1) SI1407008T1 (pt)
TW (1) TWI228420B (pt)
WO (1) WO2002097072A2 (pt)
ZA (1) ZA200309250B (pt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200776T2 (tr) * 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Burun içi grip virüsü aşısı.
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
AU2004263813B8 (en) 2003-02-25 2008-09-11 Medimmune, Llc Methods of producing influenza vaccine compositions
SI2578229T1 (sl) 2004-09-09 2013-10-30 Novartis Vaccines And Diagnostics Gmbh Zmanjšanje potencialnih iatrogenih tveganj, povezanih z antigeni cepiv
JP5147405B2 (ja) * 2004-10-06 2013-02-20 メディミューン，エルエルシー 冷蔵温度安定型インフルエンザワクチン組成物
WO2006062637A2 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics Inc. Influenza vaccination
US9161905B2 (en) * 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
TW200700078A (en) * 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Novel use
PL1909830T3 (pl) * 2005-08-02 2012-02-29 Novartis Vaccines And Diagnostics S R L Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie
EA014062B1 (ru) 2005-11-01 2010-08-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568210A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
PL2422810T3 (pl) 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2185196B1 (en) 2007-08-27 2014-06-11 Longhorn Vaccines & Diagnostics, LLC Immunogenic compositions and methods
RU2496519C2 (ru) * 2007-08-28 2013-10-27 Бакстер Интернэшнл Инк. Способ получения препарата, содержащего вирусные антигены, и применение препарата
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5415449B2 (ja) 2007-12-24 2014-02-12 ノバルティス アーゲー 吸着されたインフルエンザワクチンのためのアッセイ
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
BRPI0910963A2 (pt) 2008-04-16 2016-01-05 Glaxosmithkline Biolog Sa composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
US20110217330A1 (en) 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
WO2010125461A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
AU2010250832B2 (en) 2009-05-21 2013-10-03 Seqirus UK Limited Reverse genetics using non-endogenous pol I promoters
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
US8883481B2 (en) 2009-10-20 2014-11-11 Novartis Ag Reverse genetics methods for virus rescue
GB0918830D0 (en) * 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
NZ600254A (en) 2009-12-03 2013-10-25 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
DK2356983T3 (da) 2009-12-03 2013-03-11 Novartis Ag Cirkulation af bestanddele under homogenisering af emulsioner
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PT2343052E (pt) 2009-12-03 2013-08-28 Novartis Ag Filtração hidrofílica durante o fabrico de adjuvantes de vacinas
KR20130048208A (ko) 2010-03-11 2013-05-09 이뮨 디자인 코포레이션 인플루엔자 백신
CA2796213A1 (en) 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
PT3103784T (pt) 2010-05-12 2019-05-20 Novartis Ag Preparação de uma emulsão óleo-em-água que compreende esqualeno
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
KR20130081659A (ko) 2010-06-01 2013-07-17 노파르티스 아게 인플루엔자 백신 항원의 농축 및 동결건조
EP2575872B1 (en) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
CA2815275C (en) 2010-10-27 2023-09-19 Glaxosmithkline Biologicals S.A. Immunogenic compositions derived from shigella
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
US20130315955A1 (en) * 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
HK1214959A1 (zh) 2012-12-03 2016-08-12 Novartis Ag 流感病毒重配
AU2014204826A1 (en) 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
AU2014264501A1 (en) 2013-05-10 2015-12-10 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
US10329537B2 (en) 2013-06-06 2019-06-25 Seqirus UK Limited Influenza virus reassortment
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
EP3075393A4 (en) 2013-11-29 2017-08-16 Terumo Kabushiki Kaisha Adjuvant composition, vaccine composition comprising same, and method for producing same
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
AU2018309648B2 (en) 2017-08-04 2024-10-31 Syngenta Crop Protection Ag Methods and compositions for targeted genomic insertion
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3917567A1 (en) 2019-01-30 2021-12-08 GlaxoSmithKline Biologicals SA Oil/surfactant mixtures for self-emulsification
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
RU2754398C1 (ru) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Способ получения четырехвалентной вакцины для профилактики гриппа
JP2023532944A (ja) 2020-06-30 2023-08-01 セキラス ユーケー リミテッド 水中油型エマルジョンアジュバントの低温濾過
IE20210235A1 (en) 2020-10-20 2023-08-16 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US639A (en) 1838-03-17 of boston
US5520A (en) 1848-04-18 Oegan-pipb
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
AU626049B2 (en) * 1989-05-29 1992-07-23 Lion Corporation Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5616487A (en) 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
ATE214603T1 (de) * 1995-06-30 2002-04-15 American Cyanamid Co Stabile makrolide und makrolide imptstoff- zusammensetzungen
US20020165168A1 (en) 1995-12-16 2002-11-07 Joachim Bunger Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
DE19649895A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Schäumende Körperreinigungsmittel
CA2277911C (en) * 1997-01-13 2010-09-14 Emory University Compounds and their combinations for the treatment of influenza infection
GB9705740D0 (en) * 1997-03-20 1997-05-07 Medeva Europ Ltd A method of preservation
ATE278419T1 (de) 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
KR20010042573A (ko) * 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
FR2780278B1 (fr) * 1998-06-24 2001-01-19 Oreal Composition conditionnante et detergente et utilisation
DE19841796A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
TR200200776T2 (tr) * 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Burun içi grip virüsü aşısı.
CO5200838A1 (es) * 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
AU765824B2 (en) * 1999-09-24 2003-10-02 Smithkline Beecham Biologicals (Sa) Vaccines
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
BR0014778A (pt) 1999-10-19 2002-07-16 Procter & Gamble Composição antimicrobiana, processos para matar bactérias, para desativar vìrus, para aperfeiçoar a saúde global de um mamìfero, para reduzir a ausência de pessoas, utilização de composição, produto antimicrobiano e conjunto de tratamento pessoal antimicrobiano
NZ525076A (en) * 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US9856414B2 (en) 2013-06-10 2018-01-02 Dober Chemical Corp. Compositions, systems and methods of making coated additive components

Also Published As

Publication number Publication date
FR13C0072I1 (fr) 2014-01-31
ZA200309250B (en) 2005-05-25
EP1407008B1 (en) 2009-01-07
CZ298697B6 (cs) 2007-12-27
CZ20033253A3 (cs) 2004-04-14
KR20040025682A (ko) 2004-03-24
NZ529755A (en) 2005-11-25
DE60230760D1 (de) 2009-02-26
HUP0400445A2 (hu) 2004-07-28
IL188834A (en) 2011-01-31
HK1067891A1 (en) 2005-04-22
ES2318020T3 (es) 2009-05-01
AU2006200742A1 (en) 2006-03-16
AU2006200742C1 (en) 2014-10-16
SI1407008T1 (sl) 2009-06-30
CO5540349A2 (es) 2005-07-29
MY134424A (en) 2007-12-31
WO2002097072A3 (en) 2003-04-24
HUP0400445A3 (en) 2011-06-28
AU2002344182B2 (en) 2006-01-05
IL188834A0 (en) 2009-02-11
PT1407008E (pt) 2009-02-26
BRPI0210076B8 (pt) 2021-05-25
CN1533434A (zh) 2004-09-29
NO20035208D0 (no) 2003-11-24
CN1279165C (zh) 2006-10-11
CN101069744B (zh) 2012-04-25
WO2002097072A2 (en) 2002-12-05
DK1407008T3 (da) 2009-04-27
CA2448208A1 (en) 2002-12-05
KR100871021B1 (ko) 2008-11-27
IL158931A (en) 2008-04-13
AU2006200742B2 (en) 2010-05-27
MXPA03010944A (es) 2005-04-08
US20040241187A1 (en) 2004-12-02
PL366990A1 (en) 2005-02-07
AU2006200742C9 (en) 2015-03-26
AU2002344182C1 (en) 2014-11-06
TWI228420B (en) 2005-03-01
PL206435B1 (pl) 2010-08-31
US7316813B2 (en) 2008-01-08
AR036039A1 (es) 2004-08-04
EP2039761A1 (en) 2009-03-25
CN101069744A (zh) 2007-11-14
NO335212B1 (no) 2014-10-20
CY1108930T1 (el) 2014-07-02
ATE420159T1 (de) 2009-01-15
US20080181914A1 (en) 2008-07-31
EP2495314A1 (en) 2012-09-05
JP4074582B2 (ja) 2008-04-09
HU229368B1 (en) 2013-11-28
WO2002097072A8 (en) 2004-02-19
EP1407008A2 (en) 2004-04-14
CA2448208C (en) 2011-11-29
JP2004527264A (ja) 2004-09-09
BRPI0210076B1 (pt) 2020-01-07
BRPI0210076A8 (pt) 2017-05-23

Similar Documents

Publication Publication Date Title
BR0210076A (pt) Preparação de vìrus da influenza inativado, vacina de influenza, métodos para a preparação de um antìgeno de hemaglutinina estável e para a profilaxia da doença ou infecção de influenza em um indivìduo, e, uso de alfa-tocoferol ou de um seu derivado
JP2004527264A5 (pt)
BR0014281A (pt) Vacina contra vìrus de gripe intranasal
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
BR112022024248A2 (pt) Vacinas de combinação à base de ácido nucleico
BR0113822A (pt) Vacina
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
ES2398451T3 (es) Coadyuvante para vacunas
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
BR0205684A (pt) Compostos cìclicos fundidos e seu uso medicinal
BRPI0707300B8 (pt) vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
BRPI9609414B8 (pt) combinação de vacina e kit para produzir a mesma.
BR0113301A (pt) Composição de vacina em dose sólida oral
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
BR0014285A (pt) Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
BR0000126A (pt) Adjuvantes para uso em vacinas
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
AR052625A1 (es) Nueva composicion
BR0208301A (pt) Vacinas de ácido nucléico para prevenção de infecção por flavivìrus
PT102548A (pt) Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
BRPI0407950A (pt) processo para a preparação de uma composição de higiene pessoal
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
ATE214615T1 (de) Impfstoffe gegen grippe
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 7/04

Ipc: C12N 7/04 (2006.01), A61K 39/145 (2006.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS BRANCH OF SMITHKLINE B

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/05/2022